down arrow

SymBio Pharmaceuticals Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3383050006
JPY
100.00
1 (1.01%)

Dec 11

TKS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Fuji Pharma Co., Ltd.
Koa Shoji Holdings Co., Ltd.
Taiko Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd.
Noile-Immune Biotech, Inc.
Healios KK
Fuso Pharmaceutical Industries Ltd.
RaQualia Pharma, Inc.
SymBio Pharmaceuticals Ltd.
SanBio Co., Ltd.
CanBas Co., Ltd.
Why is SymBio Pharmaceuticals Ltd. ?
1
With a fall in Net Sales of -27.78%, the company declared Very Negative results in Jun 25
  • The company has declared negative results for the last 10 consecutive quarters
  • The company has declared negative results in Dec 22 after 7 consecutive negative quarters
  • INTEREST(9M) At JPY 108.84 MM has Grown at inf%
  • NET PROFIT(HY) At JPY -2,369.66 MM has Grown at -58.34%
  • NET SALES(Q) At JPY 382.62 MM has Fallen at -27.78%
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -56.52%, its profits have fallen by -92%
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -56.52% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is SymBio Pharmaceuticals Ltd. for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
SymBio Pharmaceuticals Ltd.
-56.52%
-0.97
39.62%
Japan Nikkei 225
28.54%
1.11
25.75%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
3.58%
EBIT Growth (5y)
1.88%
EBIT to Interest (avg)
-451.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.86
Sales to Capital Employed (avg)
0.72
Tax Ratio
0.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.63%
ROE (avg)
9.20%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.38
EV to EBIT
-1.22
EV to EBITDA
-1.22
EV to Capital Employed
10.70
EV to Sales
2.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-877.08%
ROE (Latest)
-126.18%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET PROFIT(HY)

Higher at JPY -2,369.66 MM

RAW MATERIAL COST(Y)

Fallen by 0.52% (YoY

-28What is not working for the Company
INTEREST(9M)

At JPY 108.84 MM has Grown at inf%

NET PROFIT(HY)

At JPY -2,369.66 MM has Grown at -58.34%

NET SALES(Q)

At JPY 382.62 MM has Fallen at -27.78%

ROCE(HY)

Lowest at -105.8%

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.45%

Here's what is working for SymBio Pharmaceuticals Ltd.
Net Profit
Higher at JPY -2,369.66 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (JPY MM)

Raw Material Cost
Fallen by 0.52% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for SymBio Pharmaceuticals Ltd.
Net Profit
At JPY -2,369.66 MM has Grown at -58.34%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (JPY MM)

Interest
At JPY 108.84 MM has Grown at inf%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales
At JPY 382.62 MM has Fallen at -27.78%
over average net sales of the previous four periods of JPY 529.77 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Inventory Turnover Ratio
Lowest at 2.45% and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."